Automatic Website Traffic RSS

FDA shares guidance to drugmakers developing non-opioid pain medicines

The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid addiction crisis. read more

FDA Looks To Streamline Development of Non-Opioid Painkillers

New draft guidelines suggest the FDA is open to exercising regulatory flexibility for non-opioid drugs being developed for chronic pain. read more

FDA issues new draft guidance to find opiate alternatives

Journavx (suzetrigine) 50 mg oral tablets, the first-in-class non-opioid analgesic for moderate to severe acute pain, was approved by the FDA in January 2025, marking a regulatory milestone that the ... read more

New type of non-opioid pain medication approved by FDA

(The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s ... read more

FDA Issues Draft Guidance On Non-Opioid Options for Chronic Pain Treatment

WASHINGTON - The Food and Drug Administration on Wednesday released a draft guidance to accelerate the use of safe and effective non-opioid treatments for chronic pain and reduce prescription-related ... read more

FDA pushing non-opioid path for chronic pain

The FDA is aiming to reduce reliance on opioids by providing guidance on the development of prescription non-opioid treatments for chronic pain. read more